Immunomodulator combination versus mono therapy: Does combination therapy have an impact on infliximab therapy?
Digestive and Liver Disease · 2024
DOI: 10.1016/j.dld.2023.11.039 ↗Kurz gefasst
Leserbrief in der Zeitschrift Digestive and Liver Disease, 2024. Verfasst von Ilhami Yuksel und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Ankara Bilkent City Hospital, Ankara, Turkey; Department of Gastroenterology, Ankara Yildirim Beyazit University Scho…. Hauptthemen laut MEDLINE: Immunologic Factors, Antibodies, Monoclonal. Die Arbeit nennt 10 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Ankara Bilkent City Hospital, Ankara, Turkey; Department of Gastroenterology, Ankara Yildirim Beyazit University School of Medicine, Ankara, Turkey. Electronic address: yukselilhami@hotma…
- Department of Gastroenterology, Ankara Bilkent City Hospital, Ankara, Turkey.
Zitieren
APA
Yuksel, I., Cagir, Y., & Atay, A. (2024). Immunomodulator combination versus mono therapy: Does combination therapy have an impact on infliximab therapy?. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2023.11.039
Vancouver
Yuksel I, Cagir Y, Atay A. Immunomodulator combination versus mono therapy: Does combination therapy have an impact on infliximab therapy?. Digestive and Liver Disease. 2024. doi:10.1016/j.dld.2023.11.039
BibTeX
@article{Yuksel2024,
author = {Yuksel, Ilhami and Cagir, Yavuz and Atay, Ali},
title = {Immunomodulator combination versus mono therapy: Does combination therapy have an impact on infliximab therapy?},
journal = {Digestive and Liver Disease},
year = {2024},
doi = {10.1016/j.dld.2023.11.039}
}
EUVIMED